Biomarker StrategyThe OncoSignature test by Acrivon effectively distinguishes responders from non-responders in endometrial cancer, demonstrating a statistically significant classification power.
Clinical EfficacyAcrivon Therapeutics' ACR-368 shows promising efficacy in endometrial cancer with response rates significantly surpassing standard of care and other developmental-stage treatments.
Safety ProfileACR-368 maintains a positive safety profile with low rates of severe hematologic events and absence of long-term toxicities, comparing favorably to antibody-drug conjugates in endometrial cancer treatment.